This report provides a detailed analysis of orphan drug coverage, funding, and pricing systems in the US, Japan, and the EU's five biggest pharmaceutical markets (France, Germany, Italy, Spain, and the UK). It also tracks recent developments in orphan drug pricing and reimbursement across these seven countries, and describes the impact of those changes on rare disease treatments in general, and on specific products in particular. Finally, it addresses some of the major issues facing payers and orphan drug manufacturers, highlighting the way these have been handled by both parties through individual case studies.

This Datamonitor Healthcare report contains a Strategy module.